Compare MSC & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MSC | OPK |
|---|---|---|
| Founded | 2000 | 2007 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 753.1M | 1.0B |
| IPO Year | 2018 | 1995 |
| Metric | MSC | OPK |
|---|---|---|
| Price | $3.48 | $1.35 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $2.28 |
| AVG Volume (30 Days) | 2.3K | ★ 2.8M |
| Earning Date | 11-06-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $687,148,000.00 | $642,067,000.00 |
| Revenue This Year | $8.92 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 9.50 | N/A |
| 52 Week Low | $2.30 | $1.11 |
| 52 Week High | $7.00 | $2.04 |
| Indicator | MSC | OPK |
|---|---|---|
| Relative Strength Index (RSI) | 44.26 | 48.34 |
| Support Level | $3.37 | $1.28 |
| Resistance Level | $3.61 | $1.42 |
| Average True Range (ATR) | 0.07 | 0.05 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 59.09 | 50.32 |
Studio City International Holdings Ltd is a gaming, retail, and entertainment resort located in Cotai, Macau. It operates Studio City Casino with around 250 mass-market gaming tables; including tables for VIP rolling chip operations, and 552 gaming machines. Studio City features luxury hotel rooms, diverse food and beverage establishments, and complementary retail space. In addition, the company offers non-gaming attractions, including the world's first figure-8 Ferris wheel, a deluxe nightclub and karaoke venue, a live performance arena, an outdoor and an indoor water park. Geographically, the company derives the majority of its revenue from the Macau region.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.